Maravai Q3 revenue up 133% to $204.8M; raises 2021 guidance, provides 2022 outlook

MARAVAI LIFESCIENCES HOLDINGS, INC.

2021-Q3 EPS reported $1.14 revenue$570,796,000

Q3 revenue $204.8M (+133% YoY); net income $132.8M (+240%); Adj EBITDA $156.0M.
Nucleic Acid Production revenue $182.9M (+170% YoY) on demand for CleanCap mRNA vaccine components.
2021 guidance raised: revenue $770-780M, Adj EBITDA $570-575M, Adj diluted EPS $1.48-$1.52.
Initial 2022 revenue guidance $840-880M, representing ~11-14% growth at midpoint after adjusting for divestiture.
Completed sale of Protein Detection business; published inaugural ESG report.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.